Women's Weight Loss in Singapore: Why Your Body Fights Back and What Actually Works

Why is it so much harder for women to lose weight? If you have ever watched a male partner or colleague drop kilos by skipping dessert for two weeks while you count every calorie and see the scale barely move, you already know the answer is not willpower. The difference is hormonal and metabolic. Women's bodies are wired differently when it comes to storing and releasing fat, and that wiring changes at every major life stage.

Women's weight loss in Singapore follows this same frustrating pattern. The combination of hormonal fluctuations, stress-heavy lifestyles, and a food culture that revolves around hawker centres and social eating makes it harder still. But the biology is not destiny. Understanding why your body resists weight loss is the first step toward finding an approach that actually works with your physiology instead of against it.

This article breaks down the hormonal science behind women's weight challenges, what happens at key life stages, and what treatment options are available in Singapore today.

Why women's bodies resist weight loss

Women carry roughly 6-11% more body fat than men at any given weight. This is not a flaw. It is by design. Your body stockpiles energy reserves for pregnancy and breastfeeding, and several hormonal systems work to protect those reserves.

Oestrogen influences where your body stores fat (hips, thighs, breasts) and how readily it releases fat for energy. When oestrogen levels drop — during certain phases of your cycle, after pregnancy, or during perimenopause — your body shifts fat storage to the abdomen, where it is metabolically more stubborn.

Then there is insulin resistance. Women are more susceptible to it than commonly recognised, particularly during PCOS, perimenopause, and periods of high stress. When insulin is chronically elevated, your body stays in fat-storage mode and struggles to access stored fat for energy. You can eat in a calorie deficit and still not lose weight because your metabolic hormones are blocking the process.

Cortisol makes it worse. The stress hormone promotes visceral (abdominal) fat storage and increases cravings for high-calorie, high-sugar foods. Women tend to produce more cortisol in response to psychosocial stress than men, and the combination of work pressure, caregiving responsibilities, and sleep deprivation creates a cortisol environment that actively resists weight loss.

Leptin resistance adds another layer. Leptin is the hormone that tells your brain you are full. When you carry excess fat, leptin levels are chronically high, which sounds like it should kill your appetite. But the opposite happens. Your brain stops responding to the signal. You feel hungry even when your body has more than enough stored energy. Women experience leptin resistance at higher rates, possibly related to oestrogen interactions.

On top of all this, women have less muscle mass than men on average, which means a lower resting metabolic rate. Every kilogram of muscle burns roughly 13 calories per day at rest, and women typically carry 10-15 kg less muscle than men of similar height and weight.

PCOS and weight

Polycystic ovary syndrome affects an estimated 5-10% of women of reproductive age in Singapore. Up to 70% of women with PCOS are overweight or obese, and the relationship between PCOS and weight is bidirectional: excess weight worsens PCOS symptoms, and PCOS hormonal imbalances make weight loss harder.

The core driver is insulin resistance. In PCOS, the body overproduces insulin, which:

• Signals fat cells to store more fat and resist releasing it
• Triggers the ovaries to produce excess androgens (testosterone)
• Increases appetite and cravings, particularly for carbohydrates
• Creates a metabolic cycle where conventional dieting becomes progressively less effective

This is why many women with PCOS describe the experience of "doing everything right" and still gaining weight. The problem is not compliance. It is the underlying metabolic environment.

GLP-1 medications address this at the root by improving insulin sensitivity, reducing appetite through hormonal pathways (not willpower), and quieting food noise. The STEP 2 trial (Davies et al., The Lancet 2021) showed that patients with type 2 diabetes (a condition that shares PCOS's insulin resistance mechanism) lost 9.6% of body weight on semaglutide over 68 weeks.

For a detailed look at evidence-based approaches to PCOS weight management, see our PCOS weight loss guide.

Perimenopause and menopause

If your 40s brought unexpected weight gain, particularly around your midsection, you are not alone. Perimenopause typically begins in the mid-40s and can last 4-8 years before menopause. During this transition, declining oestrogen levels fundamentally reshape how your body stores fat.

Several things change at once. Oestrogen previously directed fat to your hips and thighs (subcutaneous fat). As it drops, fat migrates to the abdomen (visceral fat), which is metabolically active and harder to shift through diet alone. Your resting metabolic rate drops by approximately 100 calories per day during the menopausal transition, partly hormonal and partly from age-related muscle loss.

Sleep disruption compounds it. Hot flashes, night sweats, and insomnia are common during perimenopause. Poor sleep drives up cortisol, which drives up appetite and visceral fat storage. And the calorie-restriction approaches that worked in your 20s and 30s produce diminishing returns because your metabolic rate has shifted and your body has become more efficient at protecting fat stores.

GLP-1 medications work regardless of your hormonal context because they target the appetite and satiety pathways in the brain directly. The STEP 1 trial included women across a range of ages, and the results were consistent. You can read more about navigating weight loss during this transition in our menopause weight loss guide.

Postpartum weight retention

Many women in Singapore carry an extra 5-10 kg after pregnancy that refuses to budge. Hormonal recovery after childbirth takes 6 to 12 months, and during this time your metabolism is still adjusting.

Sleep deprivation is the biggest factor. New parents average 4-6 hours of fragmented sleep. Poor sleep elevates ghrelin (hunger hormone) and suppresses leptin (fullness hormone), creating a hormonal environment that promotes overeating. Postpartum thyroiditis affects 5-10% of women and can cause temporary hypothyroidism, which slows metabolism further. Add stress eating from the demands of new parenthood and reduced physical activity from recovery and infant care, and the weight stays put.

Important timing note for GLP-1 treatment: GLP-1 medications are contraindicated during pregnancy and not recommended during breastfeeding due to insufficient safety data. If you are breastfeeding, you should wait until you have finished before considering GLP-1 treatment. If you are planning another pregnancy, semaglutide should be discontinued at least two months before conception.

For women who have finished breastfeeding and are struggling with persistent postpartum weight, GLP-1 treatment may be worth discussing with a doctor. See our guide on how to get prescribed weight loss medication.

Why most diets fail women specifically

The diet industry treats weight loss as a maths problem: eat less, burn more. But women's metabolic response to calorie restriction is different from men's in ways that make traditional dieting a losing strategy.

When women reduce calories, their bodies slow their metabolic rate more aggressively than men's. This "starvation response" is an evolutionary survival mechanism. Today, it means the 1,200-calorie diet that produced results in the first month hits a wall by month three.

Severe calorie restriction also suppresses thyroid function, disrupts menstrual cycles, and increases cortisol. You lose weight on paper but feel terrible, and your body fights harder to regain every kilogram the moment you return to normal eating.

The emotional eating gap matters too. Research consistently shows that women use food for emotional regulation more frequently than men. Stress, loneliness, boredom, and hormonal shifts all trigger eating behaviour that has nothing to do with hunger. Willpower does not override biology. Understanding why emotional eating happens is more useful than trying to out-discipline it.

And yo-yo dieting makes each round harder. Each cycle of weight loss and regain reduces muscle mass (you lose both fat and muscle during dieting, but regain mostly fat). Over years, your body composition shifts unfavourably, leaving you with a lower metabolic rate and a higher body fat percentage at the same weight.

How GLP-1 medications work differently

GLP-1 medications (semaglutide, tirzepatide) do not ask you to fight your hunger through willpower. They adjust the hormonal signals that drive hunger in the first place.

GLP-1 activates receptors in the hypothalamus that regulate satiety. This reduces the biological hunger signal. You are not resisting food. You are genuinely less hungry. Patients consistently describe this as food noise going quiet for the first time.

They also improve insulin sensitivity, which matters for women with PCOS or insulin resistance. By improving how your body processes insulin, GLP-1 medications help unlock fat stores that were previously metabolically "locked." And they slow gastric emptying, so food stays in your stomach longer and you feel satisfied after smaller meals without having to consciously restrict.

What makes this relevant for women specifically: GLP-1 medications target pathways that sit upstream of hormonal conditions. Whether you are dealing with PCOS, perimenopause, postpartum shifts, or thyroid-related weight gain, the mechanism works. The clinical trials included women across age ranges and hormonal profiles, and results were consistent.

In the STEP 1 trial (Wilding et al., NEJM 2021), participants on semaglutide lost an average of 14.9% of their body weight over 68 weeks, with 86.4% losing at least 5%. These results came from real patients with real hormonal challenges, not idealised study subjects.

What to consider before starting

GLP-1 treatment is not right for everyone. Before starting, your doctor will assess several things.

BMI is the starting point. Singapore's MOH guidelines recommend pharmacotherapy for BMI 30 and above without comorbidities, or BMI 27.5 and above with conditions like diabetes, hypertension, or PCOS. Trimly's eligibility criteria start at BMI 27.5 without conditions, or BMI 24 with weight-related conditions.

Your medical history matters. Personal or family history of medullary thyroid carcinoma is a contraindication. Your doctor will also review cardiovascular health, kidney function, and current medications.

Timing around pregnancy is important. GLP-1 medications are contraindicated during pregnancy. Semaglutide should be stopped at least two months before planned conception. If you are breastfeeding, wait until you have finished.

And expectations should be realistic. GLP-1 treatment produces 10-20% body weight loss in clinical trials, but best results come from combining medication with sustainable lifestyle habits — nutrition, physical activity, and sleep.

Learn more about the full assessment process doctors follow before prescribing GLP-1 treatment.

Frequently asked questions

Can I take GLP-1 medication if I have PCOS?

Yes. GLP-1 medications are prescribed for weight management in patients with PCOS, though this is considered off-label use (GLP-1s are approved for weight management and diabetes, not PCOS specifically). The insulin-sensitising effects of GLP-1 treatment are useful for PCOS specifically, since insulin resistance is a core driver of the condition. Your doctor will assess whether GLP-1 treatment is appropriate for your specific situation.

Is GLP-1 safe during perimenopause?

Yes. GLP-1 medications have been studied in patients across age groups, including women in perimenopause and menopause. There are no specific contraindications related to menopausal status. In fact, many women in this age group find GLP-1 treatment particularly helpful because it addresses the metabolic changes (insulin resistance, visceral fat accumulation) that make weight loss harder during this transition.

How much weight can women expect to lose on GLP-1?

Clinical trial data shows average weight loss of 14.9% with semaglutide (STEP 1, Wilding et al., NEJM 2021) and up to 22.5% with tirzepatide at the highest dose (SURMOUNT-1, Jastreboff et al., NEJM 2022) over 68-72 weeks. Individual results vary based on starting weight, dose, adherence, diet, and exercise. Most patients begin noticing changes within the first 4-8 weeks of treatment.

Will I gain the weight back if I stop?

A follow-up to the STEP 1 trial (Wilding et al., Diabetes, Obesity and Metabolism 2022) showed that about two-thirds of participants regained weight within a year of stopping semaglutide. This is not a failure of the medication. Obesity is a chronic condition, and long-term medication may be appropriate, similar to how blood pressure medication manages hypertension over time. Your doctor can help you decide on the right treatment duration. Read about maintaining weight after GLP-1 treatment.

Key takeaways

• Women face unique biological barriers to weight loss, including oestrogen fluctuations, insulin resistance, cortisol, leptin resistance, and lower muscle mass
• PCOS, perimenopause, and postpartum hormonal shifts all make conventional dieting less effective
• GLP-1 medications work by targeting the hormonal drivers of hunger, bypassing the willpower problem
• Treatment is available in Singapore and can be accessed through telehealth for convenience
• If you have tried diets and exercise without lasting results, the problem may be your biology, not your effort

This article is for informational purposes only and does not constitute medical advice. Always consult your doctor before starting, stopping, or changing any medication. Individual results may vary. Trimly is a MOH-licensed telehealth clinic in Singapore (HCSA License R/25M0505/MDS/001/252).

Some uses discussed in this article may be off-label or investigational. Off-label prescribing is at the discretion of your treating doctor based on your individual health profile.

Clinical trial results are based on controlled study conditions and may not reflect real-world outcomes. Weight loss results vary depending on individual factors including starting weight, adherence, diet, and exercise. The figures cited in this article come from specific trial populations and dosing regimens.